Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I open label multi-center study to evaluate the safety, tolerability,
pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in
patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of
medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent
anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).